Fears that hormone replacement therapy can cause recurrence among survivors of gynecologic cancer may be overstated, according to a review led by Professor of Gynecologic Oncology Dr. @pedroramirezMD. spr.ly/6018B1gWpk
We’re both honored and excited to announce that Houston Methodist Hospital has been named The Best Hospital in Texas for 15 years in a row by @USNews. We’re proud to be a top-ranked hospital in the country, and ranked in 11 specialties.
ALT Houston Methodist Hospital is recognized by U.S. News & World Report as the #1 Hospital in Texas and a top-ranked hospital nationally, highlighted by a \u201CBEST HOSPITALS HONOR ROLL 2026-2027\u201D badge, next to a modern blue-lit building.
Each year, @USNews publishes a list of the top ranked hospitals in the U.S. This year, we’re both honored and excited that Houston Methodist Hospital is ranked No. 7 in the nation for Obstetrics & Gynecology.
ALT Houston Methodist Hospital recognized as a U.S. News & World Report Honor Roll Hospital and ranked #7 nationally for Obstetrics & Gynecology for 2026-2027.
In this article @Annals_Oncology GLP1 receptor agonists reduce cancer incidence. The focus is on those cancers linked to obesity @AparnaKamatMD . A retrospective study with a large sample size in people looking to lose weight . A detailed case/control type method. 41%⬇️ in cancer with GLP1 injections. It’s not clear if the effects of wt loss or the agonists are having an effect. Validation needed. Great work!!
Dr. @pedroramirezMD moderates a multidisciplinary panel discussion about the latest advances in de-escalating treatment for cervical, uterine and ovarian cancers featuring Drs. Jessica Floyd, Karolina Kilowski and @ZandBehrouz.
Watch the full discussion: spr.ly/6014BDdXM4
We are extremely proud of this amazing team achievement! IF=5.4!! This has been such an impactful journey! I am extremely grateful to all of you who have contributed to this success! Thank you!!! @IJGConline@IJGCfellows@ESGO_society@IGCSociety@MethodistHosp
We're thrilled to see IJGC reach an impact factor of 5.4 — a reflection of the influence and visibility of IJGC. We are so proud of the high quality content published and cited by other researchers. This is a milestone worth celebrating, congrats to Pedro Ramirez, Editor-in-Chief, and the entire editorial team. We are grateful for the support from our publisher Elsevier. We look forward to building on this momentum!
💉 Could #GLP1 RAs help reduce #cancer risk?
🆕 observational data found a significantly lower incidence of obesity-related cancers among GLP-1 RA users, with the greatest reduction seen with tirzepatide.
🔹 Aparna A. Kamat, MD | @Annals_Oncology
🔗 ascopost.com/news/june-2026/…
Exciting data from our @MethodistHosp team at #SGO2026 presenting on GLP-1 agonists and reduced obesity-associated cancer risk, with a striking signal in endometrial cancer. Congrats to @HsuMd Aparna Kamat , and @pedroramirezMD on a fantastic rapid-fire oral.